Journal of Medicinal Chemistry · 2019 · 14 citations · 23 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructural BiologyDrug-receptor InteractionsLigand BindingMacromolecular StructureProtein-ligand BindingReceptor-ligand InteractionsTyrosine Kinase InhibitorsBruton Tyrosine KinaseCovalent Enzyme InhibitorsCovalent InhibitorsCovalent Kinase InhibitorsCovalent Tyrosine Kinase InhibitorsEpidermal Growth Factor Receptor InhibitionMitogen-activated Protein Kinase KinaseTyrosine Kinase Inhibition
Pyrazolopyrimidines are well-established as covalent inhibitors of protein kinases such as the epidermal growth factor receptor or Bruton’s tyrosine kinase, and we recently described their potential in targeting mitogen-activated protein kinase kinase 7 (MKK7). Herein, we report the structure–activity relationship of pyrazolopyrimidine-based MKK7 inhibitors and solved several complex crystal structures to gain insights into their binding mode. In addition, we present two structures of apo-MKK7, exhibiting a DFG-out and an unprecedented DFG-in/Leu-in conformation.
23
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Zhengying Pan, Heleen Scheerens, Shyr‐Jiann Li et al. · ChemMedChem · 2006 · 675 citations